BBVA
BTAI icon

Banco Bilbao Vizcaya Argentaria’s BioXcel Therapeutics BTAI Stock Holding History

Banco Bilbao Vizcaya Argentaria’s Portfolio BTAI Stock Details BTAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-1,335
Closed -$1.13M – 688
2020
Q2 		$1.13M Hold
1,335
– – 0.04% 369
2020
Q1 		$477K Sell
1,335
-1,790
-57% -$643K 0.02% 494
2019
Q4 		$730K Buy
+3,125
New +$314K 0.02% 467

Other funds holding BTAI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AIM
Artemis Investment Management Edinburgh, United Kingdom $11.2B AUM 80.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Banco Bilbao Vizcaya Argentaria's BTAI Position: Q3 2020 in Review

Banco Bilbao Vizcaya Argentaria sold out of BioXcel Therapeutics (BTAI) in Q3 2020, closing a stake of 1,335 shares — an estimated $1.13M sold.

Banco Bilbao Vizcaya Argentaria first reported a position in BTAI in Q4 2019 and held it in 3 quarters. The position peaked at $1.13M in Q2 2020. 108 funds tracked by Wall St. Rank hold BTAI as of Q3 2020.

  • Banco Bilbao Vizcaya Argentaria reported no remaining BioXcel Therapeutics position as of Q3 2020 after selling out during the quarter.
  • Banco Bilbao Vizcaya Argentaria sold 1,335 BioXcel Therapeutics shares in Q3 2020, an estimated $1.13M.
  • Banco Bilbao Vizcaya Argentaria first reported a position in BioXcel Therapeutics in Q4 2019 and held it in 3 quarters.
  • Banco Bilbao Vizcaya Argentaria's BioXcel Therapeutics position peaked at $1.13M in Q2 2020.
  • 108 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q3 2020.

Based on Banco Bilbao Vizcaya Argentaria's 13F filing for Q3 2020, filed 12 Nov 2020.